Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.

ABSTRACT:

Purpose

Alterations in BRAF have been reported in 3% to 5% of prostate cancer, although further characterization is lacking. Here, we describe the nature of BRAF alterations in prostate cancer using a large cohort from commercially available tissue and liquid biopsies subjected to comprehensive genomic profiling (CGP).

Experimental design

Tissue and liquid biopsies from patients with prostate cancer were profiled using FoundationOne CDx and FoundationOne Liquid CDx CGP assays, respectively. Tissue biopsies from non-prostate cancer types were used for comparison (n = 275,151). Genetic ancestry was predicted using a single-nucleotide polymorphism (SNP) based approach.

Results

Among 15,864 tissue biopsies, BRAF-activating alterations were detected in 520 cases (3.3%). Th

SUBMITTER: Chehrazi-Raffle A 

PROVIDER: S-EPMC10543965 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature